Thyreos

Overview
News
Livestock Biotech?
Animal Therapeutics?
Product stageSegments
Seed
?
Next-generation vaccines and drugs
?

Thyreos is a biotechnology company specializing in developing vaccines and vaccine vectors specifically targeting herpesviruses (cold sores, genital sores, varicella zoster virus, and various veterinary pathogens) that impacts both animals and humans. These vaccines are designed to elicit strong immune responses without entering the nervous system, potentially reducing the risk of viral reactivation and transmission.

The company’s proprietary R2 Technology targets a specific viral component, R2, found in the pUL37 tegument protein, to selectively eliminate the neuroinvasive potential of viruses. Vaccines using this technology ensure that the nervous system remains virus-free while effectively boosting the immune system. Furthermore, Thyreos claims these vaccines require no adjuvants or repeated doses.

Funding and financials

Thyreos’ latest funding round was in December 2022, when it raised USD 1 million in seed funding backed by Invest Nebraska. Prior to this, in April 2022, the company received a Small Business Innovation Research (SBIR) grant from the USDA National Institute of Food and Agriculture (NIFA) to develop a vaccine targeting the Infectious Bovine Rhinotracheitis (IBR), a disease that causes respiratory illness in cattle.

HQ location:
Lincoln NE USA
Founded year:
2017
Employees:
1-10
IPO status:
Private
Total funding:
USD 1.8 mn
Last Funding:
USD 1.0 mn (Seed; Dec 2022)
Last valuation:
-
Key competitors
 
Loading...
Loading...
Loading...
Loading...
Product Overview
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Product Metrics
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Company profile
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...

EDGE Insights

Funding data are powered by Crunchbase
arrow
menuarrow
Click here to learn more
Get a demo

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.